Modified adenoviral vectors and methods of treatment using same
AssigneeBeth Israel Deaconess Medical Center, Inc.
InventorsDan H. Barouch, Ritu Bradley
Life of this patent
Estimating the term…
Abstract
The present invention relates to recombinant adenovirus serotype 5 (Ad5) vectors which harbor chimeric capsid proteins including substitutions of the corresponding regions from adenovirus serotypes having a lower seroprevalence relative to Ad5. In particular, the chimeric capsid includes modifications of both the adenoviral hexon and fiber proteins. The invention also provides methods for the treatment of diseases or disorders caused by infective agent(s) by administering the adenoviral vector(s) to a subject (e.g., a mammal, such as a human).
Claims22
A recombinant replication-defective adenovirus based upon adenovirus serotype 5 (Ad5), said recombinant replication-defective adenovirus comprising:
- (a) a chimeric hexon protein, wherein all or a portion of one or more hexon protein hypervariable region (HVR) sequences of HVR1 to HVR7 of Ad5 have been replaced with all or a portion of one or more of the corresponding hexon HVR sequences from an adenovirus serotype having a lower seroprevalence relative to Ad5, and
- (b) a chimeric fiber protein, wherein all or a portion of an Ad5 fiber knob domain sequence has been replaced with all or a portion of a fiber knob domain sequence from an adenovirus serotype having a lower seroprevalence relative to the Ad5.
-33. (canceled)
Dependencies are inferred from the claim text.